Sponsors

Cavion Appoints Spyridon Papapetropoulos, M.D., Ph.D. as Executive Vice President, Research and Development and Chief Medical Officer

Home - CBIC

CHARLOTTESVILLE, Va.--()--Cavion, Inc., a clinical stage biopharmaceutical company, announced today that Dr. Spyridon "Spyros" Papapetropoulos has joined as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Papapetropoulos will lead Cavion’s research

Senseonics and TypeZero Sign Development Agreement for Artificial Pancreas and Decision Support Systems

Home - CBIC

GERMANTOWN, Md.--(BUSINESS WIRE)--

Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and TypeZero Technologies, Inc., a personalized diabetes management company, today announced

Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer

Home - CBIC

Company Release - 7/31/2017 8:30 AM ET

CHARLOTTESVILLE, Va., July 31, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer and other hypoxia-related diseases, announced today that it has selected a premier Clinical Research Organization (CRO)

VividCortex Raises $8.5m

Home - CBIC

VividCortex, the database performance management company that helps businesses improve application performance, reliability, and uptime, today announced that it has closed an $8.5 million Series A-1 round led by Osage Venture Partners (OVP). Bull City Venture Partners also participated in the round, as did all existing investors,

Charlottesville Women in Tech